MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    The Pull Test in healthy subjects and Parkinson´s disease: quantitative pull-force measure, postugraphic and electromyographic analysis

    J.R. Perez-Sanchez, B. DeLaCasa-Fages, A. Contreras, J.M. Velázquez, A. Muñoz-González, F. Grandas (Madrid, Spain)

    Objective: To study and compare in healthy subjects and patients with Parkinson´s disease (PD) the destabilizing force needed to reach the limit of stability (LoS), the displacements of…
  • 2017 International Congress

    Immunomodulatory therapy in stiff-person syndrome (SPS): a controlled Rituximab-randomised study

    M. Amarandei (Bucharest, Romania)

    Objective: -the efficacy of the anti-CD20 antibody, Rituximab, in the treatment of patients with Stiff-person syndrome Background: SPS is a rare autoimmune progressive disorder of…
  • 2017 International Congress

    Characterization of Pisa syndrome in Parkinson’s disease.

    T. Clark, J. Nutt, F. Horak, M. Mancini, M. Jurado, T. Hullar (Portland, OR, USA)

    Objective: This study has two main objectives. The first objective is to elucidate the effects of distraction and alteration of sensorimotor inputs (visual and proprioceptive…
  • 2017 International Congress

    Elevated GM3 Plasma Concentration in Idiopathic Parkinson’s Disease: a Lipidomics Analysis

    R. Alcalay, R. Chan, C. Liong, A. Perotte, B. Zhou, E. Shorr, K. Marder, U. Kang, C. Waters, O. Levy, Y. Xu, H. Shim, I. Pe'er, G. Di Paolo (New York, NY, USA)

    Objective: To test the association between plasma lipids and Parkinson disease (PD) diagnosis. Background: PD is a common neurodegenerative disease whose pathological hallmark is the…
  • 2017 International Congress

    Development of a Clinical Outcomes Assessment (COA) in Pantothenate-Kinase Associated Neurodegeneration (PKAN): Item Generation and Clinimetric Properties

    R. Marshall, A. Collins, M. Escolar, H.A. Jinnah, T. Klopstock, M. Kruer, A. Videnovic, A. Robichaux-Viehoever, L. Swett, D. Revicki, R. Bender, W. Lenderking (Cambridge, MA, USA)

    Objective: To develop a clinical outcome assessment (COA) scale that measures key aspects of functioning and daily living in patients with pantothenate kinase-associated neurodegeneration (PKAN)…
  • 2017 International Congress

    The management of Parkinson’s disease in the Middle East countries: the MDS-middle east task force survey

    H. Khalil, Z. Aldaajani, S. Baudry, M. Abualmelh, T. Mohammad, M. Salari, M. Bhatt, S. Tabbal, N.A. Syed, B. Jeon, C. Goetz, J.A. Bajwa (Irbid, Jordan)

    Objective: The movement disorders society task force for the Middle East (MDS-Task Force for the Middle East) conducted a survey with an aim of characterizing…
  • 2017 International Congress

    Evaluating the Experience of Diagnosis in Parkinson’s Disease

    A. Robinson, E. Pearson, F. Murphy, J. Davis, C. Carroll (Plymouth, United Kingdom)

    Objective: To evaluate a newly-designed diagnosis patient pathway for Parkinson’s disease, in terms of quality measures and patient satisfaction. Background: Receiving a diagnosis of Parkinson’s…
  • 2017 International Congress

    Developing a guide to facilitate involving people with Parkinson’s and their carers in service improvement

    N. Shaw, V. Evans, J. Rideout, C. Carroll (Plymouth, United Kingdom)

    Objective: To develop an easy-to-use guide for service development project leads and patients/carers to facilitate the involvement of the latter in the development and implementation…
  • 2017 International Congress

    End of Life Care in Parkinson’s Disease

    S. Mole, S. Jackson (Exeter, United Kingdom)

    Objective: We aim to identify the current practice at the Royal Devon & Exeter NHS trust of managing Patients with PD at the end of…
  • 2017 International Congress

    Polyneuropathy in patients with Parkinson’s disease from southern Spain treatment with levodopa/carbidopa intestinal gel infusión

    F. Carrillo, S. Jesus, L. Vargas, M. Bernal, M.T. Caceres, A.D. Adarmes, M. Carballo, P. Mir (Seville, Spain)

    Objective: This study main objective is to prospectively report the 10-year incidence of polineuropathy in Parkinson´s disease patients from southern Spain treated with LCIG. Background: Patients with…
  • « Previous Page
  • 1
  • …
  • 1498
  • 1499
  • 1500
  • 1501
  • 1502
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley